Gilead Sciences, Inc. $GILD Shares Acquired by Avanza Fonder AB

Avanza Fonder AB lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 130,929 shares of the biopharmaceutical company’s stock after purchasing an additional 3,890 shares during the period. Avanza Fonder AB’s holdings in Gilead Sciences were worth $16,070,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. Corundum Trust Company INC acquired a new stake in Gilead Sciences in the 3rd quarter worth about $26,000. Howard Hughes Medical Institute purchased a new stake in Gilead Sciences during the 2nd quarter worth approximately $30,000. MTM Investment Management LLC raised its holdings in shares of Gilead Sciences by 176.0% during the third quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 176 shares during the last quarter. Kilter Group LLC acquired a new position in shares of Gilead Sciences during the second quarter valued at approximately $33,000. Finally, Millstone Evans Group LLC lifted its position in shares of Gilead Sciences by 58.7% in the third quarter. Millstone Evans Group LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 118 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Activity

In other news, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $144.23, for a total transaction of $432,690.00. Following the sale, the chief financial officer owned 179,191 shares of the company’s stock, valued at approximately $25,844,717.93. The trade was a 1.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $154.44, for a total value of $4,324,320.00. Following the completion of the transaction, the insider owned 120,288 shares in the company, valued at $18,577,278.72. This represents a 18.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 309,280 shares of company stock valued at $44,068,850. Company insiders own 0.27% of the company’s stock.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Acquisition adds OM336 (gamgertamig), a BCMAxCD3 T‑cell engager designed for rapid, deep B‑cell depletion—strengthens Gilead’s inflammation/autoimmune pipeline and provides a near‑term clinical asset that could drive future revenue if successful. Gilead Sciences to Acquire Ouro Medicines (Business Wire)
• Positive Sentiment: Major media and wire coverage confirms deal size and strategic rationale, increasing market confidence around the transaction’s credibility and near‑term impact. Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion (WSJ) Gilead to buy biotech firm Ouro Medicines in over $2 billion deal (Reuters)
• Positive Sentiment: Analyst support: Bank of America maintained a Buy rating and $162 price target, citing HIV franchise momentum and product upside—analyst backing can bolster investor sentiment. Buy Rating on Gilead (TipRanks / BofA)
• Neutral Sentiment: Health care sector strength is supporting stocks broadly, providing incidental tailwinds to GILD alongside the M&A news. Gilead nears up to $2bn deal for autoimmune biotech (Yahoo Finance)
• Neutral Sentiment: Reported March short‑interest data appear anomalous (showing zero/share changes and NaN), suggesting no clear short‑position signal from the data release. No reliable market pressure evident from short interest.
• Negative Sentiment: Deal and clinical risk: the price (up to $2.18B) is material and the asset is clinical‑stage—clinical trial failure, integration costs, or disappointments on OM336’s commercial potential could weigh on the stock. Gilead nearing up to $2 billion buyout of Ouro Medicines (Reuters)

Analysts Set New Price Targets

Several brokerages recently commented on GILD. UBS Group boosted their price target on Gilead Sciences from $145.00 to $155.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Leerink Partners raised their price objective on Gilead Sciences from $146.00 to $148.00 and gave the company an “outperform” rating in a report on Wednesday, February 11th. Morgan Stanley lifted their target price on shares of Gilead Sciences from $150.00 to $171.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 11th. Wall Street Zen raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, March 14th. Finally, HSBC increased their target price on shares of Gilead Sciences from $110.00 to $133.00 and gave the company a “hold” rating in a research report on Wednesday, December 10th. Twenty-four research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Gilead Sciences currently has a consensus rating of “Moderate Buy” and an average price target of $157.62.

Gilead Sciences Stock Up 0.1%

Shares of GILD opened at $137.34 on Tuesday. Gilead Sciences, Inc. has a 52-week low of $93.37 and a 52-week high of $157.29. The company has a market capitalization of $170.50 billion, a PE ratio of 20.29, a price-to-earnings-growth ratio of 1.80 and a beta of 0.36. The stock has a fifty day simple moving average of $142.98 and a two-hundred day simple moving average of $128.15. The company has a quick ratio of 1.40, a current ratio of 1.55 and a debt-to-equity ratio of 0.98.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The firm had revenue of $7.93 billion for the quarter, compared to analysts’ expectations of $7.68 billion. During the same quarter in the previous year, the company posted $1.90 EPS. The company’s revenue was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, equities analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be issued a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 2.4%. The ex-dividend date is Friday, March 13th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s dividend payout ratio (DPR) is presently 48.45%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.